Earnings ·
Upstream Bio reports Q3 net loss of $41.2M and plans Phase 3 trials in severe asthma and CRSwNP
UPBUpstream Bio, Inc.
Upstream Bio reported a net loss of $41.2 million for the quarter ended September 30, 2026, compared to a $33.7 million loss in the prior-year period. Research and development expenses increased to $36.6 million from $33.0 million, driven by higher personnel-related costs and clinical expenses for its verekitug programs. The company held cash, cash equivalents, and short-term investments of $207.4 million as of September 30, which is expected to fund operations through 2027. Upstream Bio announced that preparations are underway to initiate Phase 3 trials for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in the first quarter of 2027. The company operates as a clinical-stage biotechnology firm developing treatments for severe inflammatory respiratory diseases.